Genentech signed a global license deal with Alector for AL050, an investigational brain-penetrant GCase enzyme replacement therapy. The partners will develop it for Parkinson’s and other neurodegenerative diseases, targeting a large unmet need in neuroscience.
published
Genentech signed a global license deal with Alector for AL050, an investigational brain-penetrant GCase enzyme replacement therapy. The partners will develop it for Parkinson’s and other neurodegenerative diseases, targeting a large unmet need in neuroscience.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.